Jack Chapman, MD
Interventional Pain Medicine · New Braunfels, TXNPI 1710975701
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,777 of the $23,787 with a category attached, or 62.1%. 21 manufacturers reported payments, led by Abbott at 30.2% of the total. 2025 is the largest year on record at $7,813, 3.6 times the $2,191 reported in 2019.
Across 541 payments — averaging $43.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Si-bone, Inc.$6K
- Medtronic$4K
- Painteq LLC$2K
- Boston Scientific$1K
- SPR Therapeutics, Inc$710
- plus $2K from 15 others
What the payments were for
- Consulting fees$5,50023%
- Travel & lodging$3,08313%
- Food & beverage$14,77762%
- Education$4272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 330 | $7,177 |
| Si-bone, Inc. | 32 | $6,377 |
| Medtronic(2 entities) | 59 | $3,727 |
| Painteq LLC | 52 | $2,194 |
| Boston Scientific | 10 | $1,272 |
| SPR Therapeutics, Inc | 11 | $710 |
| MML US, Inc. | 9 | $475 |
| Nevro Corp. | 7 | $332 |
| Relievant Medsystems, Inc. | 4 | $298 |
| Stryker | 3 | $271 |
| Glaukos Corporation | 2 | $239 |
| Globus Medical | 5 | $179 |
| Saluda Medical Americas, Inc. | 2 | $153 |
| Flowonix Medical Incorporated | 2 | $110 |
| Nalu Medical, Inc. | 4 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $79 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Eagle Pharmaceuticals, Inc. | 1 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Vertos Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IFUSE IMPLANT SYSTEM$5,500
- SYNCHROMEDII$1,152
- PAINTEQ$852
- Intracept$750
- PROCLAIM$727
- INTELLIS$676
- OCTRODE$539
- SPRINT PNS System$359
- Senza$267
- ReActiv8$247
- Proclaim Family of SCS IPGs$223
- SPINEJACK$173
- Proclaim Plus SCS with FlexBurst360$169
- VANTA ADAPTIVESTIM$158
- INTELLIS ADAPTIVESTIM$153
- SYNCHROMED$146
- Axium$127
- Proclaim IPG$114
- Intracept RF Probe$105
How this compares
$23,787 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,517 | $51,452 |
| Xtampza ErOxycodone Myristate | 20 | $13,262 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 327 | $12,246 |
| Fentanyl | 106 | $11,229 |
| Morphine Sulfate ErMorphine Sulfate | 132 | $4,308 |
| Oxycodone Hcl | 191 | $4,103 |
| Gabapentin | 167 | $3,588 |
| Hydrocodone-IbuprofenHydrocodone/Ibuprofen | 12 | $3,153 |
| Hydromorphone Hcl | 186 | $2,975 |
| Tramadol Hcl | 204 | $2,095 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 84 | $1,898 |
| Tramadol Hcl ErTramadol Hcl | 20 | $1,890 |
| Pregabalin | 105 | $1,791 |
| Tizanidine Hcl | 139 | $1,517 |
| Buprenorphine Hcl | 18 | $1,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $33 | $13,26220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in New Braunfels
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
- Thomas WhiteShenandoah$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.